Fiche publication
Date publication
novembre 2019
Journal
Archives of cardiovascular diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MALOUF Gabriel
Tous les auteurs :
Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, Roden DM, Moslehi JJ, Salem JE
Lien Pubmed
Résumé
Abiraterone and enzalutamide are recently-approved androgen deprivation therapies (ADTs) for metastatic prostate cancer, with unknown cardiac safety profiles. Abiraterone has a propensity to hypermineralocorticism on top of androgen deprivation, so might carry an additional risk for atrial tachyarrhythmia (AT) and heart failure (HF) compared with other ADTs.
Mots clés
Abiraterone, Abiratérone, Androgen deprivation therapy, Anti-androgène, Atrial fibrillation, Enzalutamide, Fibrillation auriculaire, Heart failure, Insuffisance cardiaque
Référence
Arch Cardiovasc Dis. 2019 Nov 1;:
